Acelyrin's IL-17 inhibitor fails to hit primary endpoint in key study after splashy IPO

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

Acelyrin said Monday that its lead drug izokibep failed to meet the primary endpoint in a Phase IIb/III trial in patients with hidradenitis suppurativa …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Acelyrin's IL-17 inhibitor fails to hit primary endpoint in key study after splashy IPO

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Are programs with compounded GLP-1s safe for your population?

Ace­lyrin's IL-17 in­hibitor fails to hit pri­ma­ry end­point in key study af­ter splashy IPO

Senior Reporter

News Reporter

Sign up to read this article for free.

Acelyrin's IL-17 inhibitor fails to hit primary endpoint in key study after splashy IPO